armagan aral atx-oros-mph functional outcomes

Here, we assess the functional outcomes of the oral delivery system of osmotic release methylphenidate (OROS-MPH) and atomoxetine (ATX) from the retrospective review of the chart last two years in the clinic. The sample consisted of 375 children with ADHD between the ages of 6 and 14 years. The sample was evaluated in three visits (baseline, 4-7 weeks, and 9-12 weeks). Linear mixed-effects models were performed with outcome measures of difference in ADHD symptoms and functional impairment.
Results: After 9-12 weeks, OROS-MPH and ATX were statistically equal for total Weiss Functıonal Impairment Rating Scale – Parent Report (WFIRS-P) scores ( difference in slope is β= 0.004, p=1.000). However, OROS-MPH was superior to ATX in terms of school domain (difference in slope is β = 0.139 p < .001); ATX was superior in the family domain (slope difference in slope is β = 0.103, p < .001). The other domains of functioning both were not responsive to pharmacotherapy and were insignificant between the two medications.

本研究旨在评估过去两年临床记录中，渗透压释放甲基苯丙胺（OROS-MPH）和盐酸Atomoxetine（ATX）口服给药系统的功能结果。样本包括375名6至14岁的注意力缺陷多动障碍（ADHD）儿童。样本在三次访问中（基线、4-7周和9-12周）进行了评估。采用线性混合效应模型，以ADHD症状差异和功能损害差异为结果指标。结果：在9-12周后，OROS-MPH和ATX在总Weiss功能性损害评分量表-家长报告（WFIRS-P）得分上具有统计学意义上的等同性（斜率差异β=0.004，p=1.000）。然而，在学业领域，OROS-MPH优于ATX（斜率差异β=0.139，p<0.001）；在家庭领域，ATX表现更佳（斜率差异β=0.103，p<0.001）。其他功能领域对药物治疗均无反应，两种药物之间的差异不显著。